Talphera, Inc.
NASDAQTalphera just reported Q1 2026 results after the close on May 13, and the headline number was better than feared. EPS came in at $(0.04), beating the $(0.07) estimate — a meaningful outperformance for a pre-revenue micro-cap biotech that closed the day at $0.86. Revenue was effectively nil, consistent with the company's clinical-stage status, but the loss rate is narrowing. The…
Snapshot as of 28 Jun 2026
Talphera just reported Q1 2026 results after the close on May 13, and the headline number was better than feared. EPS came in at $(0.04), beating the $(0.07) estimate — a meaningful outperformance for a pre-revenue…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for TLPH — free to start on ORTEX.
Sign up for free →Open TLPH on ORTEX